SPM-2 (fadraciclib)
Solid Tumors & Hematologic Malignancies
Phase 2Active
Key Facts
About Sumitomo Pharma
Sumitomo Pharma is a research-driven pharmaceutical company with a mission to deliver innovative therapeutic solutions for serious unmet medical needs. Its strategic direction is built on a foundation of internal R&D and strategic acquisitions, such as the merger with Myovant Sciences and the acquisition of Tolero Pharmaceuticals, to bolster its pipeline in key therapeutic areas. The company faces challenges from patent expirations but is actively investing in next-generation modalities like cell and gene therapies to drive future growth.
View full company profile